NCT03055221View on ClinicalTrials.gov

TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 10, 2005

Primary Completion Date

February 25, 2014

Study Completion Date

February 25, 2014

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Intravenous Treprostinil

Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY